Navigation Links
Dynatronics Announces Positive Financial Results for Quarter
Date:11/13/2009

SALT LAKE CITY, Nov. 13 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced results for its fiscal first quarter ended September 30, 2009.

Net income for the fiscal first quarter was $68,625 ($.01 per share), compared to a net loss of $138,951 ($.01 per share) for the comparable prior year period. Sales for the quarter increased 3.6 percent to $8,282,463, compared to $7,996,149 for the first quarter of the prior fiscal year.

"Generating our fourth consecutive profitable quarter is gratifying in light of these challenging economic times," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "Both sales and net income before tax improved by approximately $300,000 for the quarter ended September 30, 2009, compared to the same quarter of the prior fiscal year."

Over the past two years, Dynatronics has implemented critical strategies to expand distribution and sales while at the same time undertaking an aggressive cost-reduction campaign to improve efficiencies. "These strategies are now beginning to bear fruit," added Cullimore. "The challenges of the national and world economy have made that progress more difficult and a little slower than anticipated. However, as the national economy improves over the next year, we are positioned to more fully realize the potential from the strategic plans we have implemented."

Initiatives to drive sales have also been underway. During the quarter ended September 30, 2009, Dynatronics announced a new preferred vendor agreement with Western Rehabilitation Health Network's 114 clinics. Dynatronics also expanded its direct sales force by 25 percent to 50 sales representatives. "These are only the beginning of our sales expansion efforts," said Larry K. Beardall, executive vice president of sales and marketing. "We plan to announce additional preferred vendor agreements very soon that will help drive sales to new levels."

Dynatronics plans to launch its new e-commerce Web site next month. This site will give customers an easier way to place orders and obtain information about their accounts. "In addition, this new system will allow our sales representatives to be more effective by having an abundance of product information available to them electronically," added Beardall. "Not only is our e-commerce solution expected to improve sales, but it will significantly reduce our transactional costs, thus enabling us to accommodate higher sales without significantly increasing overhead."

Dynatronics has scheduled a conference call for investors on Friday, November 13, 2009, at 1:30 p.m. ET. Those wishing to participate should call 800-861-4084 and use passcode 9921511.

A summary of the financial results for the three months ended September 30, 2009, follows:

                      Summary Selected Financial Data
                    Statement of Operations Highlights

                                                Three Months Ended
                                                   September 30,
                                                2009          2008
                                                ----          ----
    Net sales                               $8,282,463    $7,996,149
    Cost of sales                            5,103,121     4,800,508
                                             ---------     ---------
      Gross profit                           3,179,342     3,195,641

    SG&A expenses                            2,712,368     2,976,647
    R&D expenses                               215,968       262,029
    Other expense, net                         109,231       147,794
                                               -------       -------
      Net income (loss) before income taxes    141,775      (190,829)

    Income tax (provision) benefit             (73,150)       51,878
                                               -------        ------

      Net income (loss)                        $68,625     $(138,951)
                                               =======     =========

    Net income (loss) per diluted share           $.01         $(.01)
                                                  ====         =====



                        Balance Sheet Highlights

                                          September 30,     June 30,
                                              2009            2009
                                              ----            ----
    Cash                                    $385,153        $141,714
    Accounts receivable                    4,818,809       4,739,727
    Inventories                            6,312,906       6,199,251
    Total current assets                  12,389,266      12,003,068
    Total assets                          17,412,796      17,087,289

    Accounts payable                       1,843,377       1,795,520
    Accrued expenses                         462,980         446,327
    Line of credit                         5,027,943       4,602,651
    Total current liabilities              8,122,750       7,785,881
    Total liabilities                     10,918,387      10,667,540
    Total liabilities and equity         $17,412,796     $17,087,289

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding expected improvement in economic conditions, additional benefits to be obtained from the launch of the e-commerce system, and the anticipated continuing benefits in future periods from the cost-reduction initiative. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2009.

SOURCE Dynatronics Corporation


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
2. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
3. Dynatronics to Release First Quarter Results Friday, November 13, 2009; Conference Call Set for 1:30 p.m. ET
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Datta ... M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a ... Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
Breaking Medicine News(10 mins):